Google Alert - "Myeloproliferative neoplasms" OR "polycythemia vera" OR myelofibrosis OR "essential thrombocythemia" · Scour

Syntara Wins FDA Backing for Pivotal Amsulostat Trial in Myelofibrosis

Takeda takes rusfertide's US rights; Protagonist opts out for cash

Pharmaceutical Stock Pulling Back Before Earnings - Schaeffer's Investment Research

Ajax Therapeutics, Dana-Farber synthesize JAK2 degradation inducers

LLY Expands Oncology Pipeline With $2.3B Ajax Therapeutics Acquisition

Eli Lilly to Acquire Ajax Therapeutics in $2.3 Bn Deal to Strengthen Blood Cancer Pipeline

Eli Lilly Announces Acquisition of Ajax Therapeutics for $2 Billion

Protagonist Exercises Rusfertide U.S. Opt-Out Right Under Takeda Collaboration

Syntara Receives Positive FDA Feedback for Myelofibrosis Drug Amsulostat

Lilly aims to clean up in JAK inhibition | ApexOnco

Incyte Q1 2026 EPS Tops Expectations by 29.3%, Revenue Up 21%

Syntara Wins FDA Backing for Pivotal Amsulostat Trial in Myelofibrosis

Protagonist Exercises Rusfertide U.S. Opt-Out Right Under Takeda Collaboration

Pegylated Interferon Shows Activity Across Hematologic Neoplasms

Protagonist Exercises Rusfertide U.S. Opt-Out Right Under Takeda Collaboration

Eli Lilly Moves Boldly into Next-Generation Blood Cancer with $2.3B Ajax Therapeutics Acquisition

Lilly adds potential first-in-class Type II JAK2 inhibitor to haematology portfolio

New deal pushes Lilly beyond obesity and deeper into next wave oncology

Lilly to buy biopharma company Ajax Therapeutics to advance outcomes for patients with ...

Eli Lilly to buy Ajax Therapeutics for up to $2.3 billion in blood cancer bet

Log in to enable infinite scrolling